The Scottish Government is investing $ 27 million in Valneva’s Covid-19 production; Moderna collaborates with Latin American Pharma – Endpoints News
The Scottish Government is investing $ 27 million in Valneva’s Covid-19 production;  Moderna collaborates with Latin American Pharma – Endpoints News

The Scottish Government is investing $ 27 million in Valneva’s Covid-19 production; Moderna collaborates with Latin American Pharma – Endpoints News

Valneva’s Scottish unit has Received a $ 27 million grant to fund R&D for the manufacture of its Covid-19 vaccine VLA2001.

The investment comes from the country’s economic development agency. Two grants will spread the money over the next three years and benefit the production site in Livingston.

One grant worth $ 16.65 million will support research and development related to the production of VLA2001. Another, worth $ 9.9 million, will support R&D for the production of other diseases. Among these other vaccines is VLA1553, a single-shot vaccine against the mosquito-borne viral infection chikungunya. It is also manufactured in Livingston.

“From the only inactivated, whole virus Covid-19 vaccine candidate in clinical development in Europe to the most clinically advanced vaccine candidate against chikungunya in the world, Scottish Enterprises’ investment will support progress across Valneva’s research and development portfolio – as well as jobs and growth in Scotland , ”Said CEO Thomas Lingelbach in a statement.

Moderna collaborates with Latin American Pharma

In a move to promote the commercialization of Modernas Covid-19 shots in Latin America, the biotech has entered into an agreement with a drug based on the continent to help manufacture and distribute its shots.

Adium Pharma will commercialize Spikevax across 18 Latin American countries. That list includes Brazil, Mexico, Colombia and Argentina. The company will also look to add up to 100 people to its team.

Stéphane Bancel

“Our new partnership with Adium will help ensure broad access and delivery of our Moderna Covid-19 vaccine to humans across Latin America,” said CEO Stéphane Bancel. “A presence in Latin America is an important part of our global commercial strategy. These partnerships and the expansion of our global commercial footprint position Moderna to play an important role in providing health security against Covid-19 and future vaccine-preventable diseases.”

Moderna has only been granted emergency permits in five of these countries so far, but Moderna’s Roman Saglio told Bloomberg that the agreement, which will lead to a significant increase in production from Moderna, will help the company to be a leading vaccine supplier to the region.

Leave a Reply

Your email address will not be published.